Table 1 Patient population characteristics
Total | FF | MF | FP | |
|---|---|---|---|---|
N=452 | N=229 | N=108 | N=115 | |
Age (Mean, (SD)) | 36.2 (13.9) | 36.5 (13.7) | 35.8 (13.7) | 36.1 (14.6) |
Gender (% females) | 52.2% | 49.8% | 53.7% | 55.7% |
Body mass index (Mean, (SD)) | 24.1 (3.7) | 24.1 (3.8) | 24.3 (3.9) | 23.9 (3.5) |
Country of origin (N, %): | ||||
France | 163 (36.1%) | 82 (35.8%) | 38 (35.2%) | 43 (37.4%) |
Germany | 174 (38.5%) | 88 (38.4%) | 43 (39.8%) | 43 (37.4%) |
Spain | 115 (25.4%) | 59 (25.8%) | 27 (25.0%) | 29 (25.2%) |
ARIA severity (N, %): | ||||
Mild intermittent | 54 (12.2%) | 29 (12.9%) | 10 (9.6%) | 15 (13.2%) |
Moderate/severe intermittent | 147 (33.3%) | 81 (36.2%) | 38 (36.5%) | 28 (24.6%) |
Moderate/severe persistent | 241 (54.5%) | 114 (50.9%) | 56 (53.8%) | 71 (62.3%) |
Number of concomitant conditions reported in the previous 3 months (mean, SD) | 0.96 (1.14) | 0.96 (1.07) | 1.00 (1.25) | 0.92 (1.16) |
Number of concomitant medications taken in the previous 3 months (mean, SD) | 1.60 (0.67) | 1.61 (0.67) | 1.57 (0.61) | 1.60 (0.74) |
Number of patients who ever experienced both ocular and nasal symptoms (N, %) | 324 (71.7%) | 162 (70.7%) | 81 (75.0%) | 81 (70.4%) |